MB05032

Short Summary : GNG inhibitor,special and efficacious

Category : Others|FBPase

Purity : 0.98

CAS Number : 261365-11-1

Formula : C11H15N2O4PS

Molecular Weight : 302.29

SMILE : NC1=NC(C2=CC=C(P(O)(O)=O)O2)=C(CC(C)C)S1

Solubility : Soluble in DMSO

Storage : Store at -20°C

Description : MB05032 is a potent and selective GNG inhibitor targeted the AMP binding site of fructose 1,6-bisphosphatase (FBPase) with an IC50 value of 16 nM [1].Gluconeogenesis (GNG) is a metabolic pathway which could result in the generation of glucose from certain non-carbohydratecarbon substrates.In vitro: MB06322 inhibited glucose synthesis by human hepatocytes over a narrow concentration range with full inhibition achieved at 1 M in a concentration-dependent manner [2]. MB05032 inhibited human liver FBPase with a potency (IC50 of 16 1.5 nM) significantly greater than the natural inhibitor, AMP (IC50 of 1 M), and the most well characterized AMP mimetic, ZMP (IC50of 12 1.4 M). MB05032 inhibited rat FBPase 3-fold weaker (IC50 of 61 4 nM) than human FBPase, whereas AMP was 20-fold weaker as an inhibitor [1]. In islet -cells,inhibition of FBPase activity by MB05032 led to a significant increase of their glucose utilization and cellular ATP to ADP ratios and consequently enhanced GSIS in vitro [2].In vivo: In male ZDF rats, oral administration of MB06322 resulted in dose-dependent inhibition of [14C]bicarbonate incorporation into glucose. Maximal GNG inhibition (80%) is achieved at 100C300 mg/kg MB06322. In MB06322-treated rats, intermediates upstream of FBPase WERE elevated 1.5- to 3.1-fold relative to vehicle-treated mice. MB06322 treatment also resulted in elevated lactate levels (79%) only in aged ZDF rats. [2]. Oral administration of MB06322 to young (8C9 weeks old) ZDF rats with mild diabetes (basal insulin levels of 7.7 0.7 ng/ml) and aged (12C13 weeks) ZDF rats with overt diabetes (basal insulin levels of 0.65 0.16 ng/ml) lowered the level of glucose in a dose-dependent manner [1]. The doseCdependent response is relatively steep, with 6C10 mg/kg and 30C100 mg/kg being the approximate doses associated with minimal and maximal activity, respectively. After drug administration 2.5C5 h, glucose lowering occurs rapidly with maximal effects [1]. References:[1] Erion M D, van Poelje P D, Dang Q, et al. MB06322 (CS-917): A potent and selective inhibitor of fructose 1, 6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes[J]. Proceedings of the National Academy of Sciences, 2005, 102(22): 7970-7975.[2] Zhang Y, Xie Z, Zhou G, et al. Fructose-1, 6-bisphosphatase regulates glucose-stimulated insulin secretion of mouse pancreatic -cells[J]. Endocrinology, 2010, 151(10): 4688-4695.

Download datasheet